BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
- Conditions
- Alzheimer's Disease
- Interventions
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 586
- Registration Number
- NCT06976203
- Locations
- 🇺🇸
Local Institution - 0072, Fullerton, California, United States
🇺🇸Local Institution - 0091, Inglewood, California, United States
🇺🇸Local Institution - 0095, Irvine, California, United States
A Study to Evaluate Treatment Patterns and Effectiveness of Luspatercept
- Conditions
- Myelodysplastic Syndromes (MDS)
- Interventions
- Drug: Erythropoiesis-stimulating agent (ESA)
- First Posted Date
- 2025-05-14
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 430
- Registration Number
- NCT06971185
- Locations
- 🇺🇸
Bristol Myers Squibb, Princeton, New Jersey, United States
A Study to Assess Drug Levels, Tolerability and Absolute Biological Availability of Single-dose of BMS-986446 in Healthy Participants
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2025-05-02
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 46
- Registration Number
- NCT06955741
- Locations
- 🇺🇸
Anaheim Clinical Trials LLC (ACT), Anaheim, California, United States
🇺🇸Local Institution - 10000, Anaheim, California, United States
🇺🇸Local Institution - 9999, Anaheim, California, United States
A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Psoriasis
- Conditions
- Psoriasis
- Interventions
- Biological: Any biologic treatment for psoriasis
- First Posted Date
- 2025-05-01
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 2000
- Registration Number
- NCT06952465
- Locations
- 🇯🇵
Local Institution, Tokyo, Japan
🇯🇵Medical Data Vision, Inc, Tokyo, Japan
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder
- Conditions
- Bipolar-I Disorder With Mania or Mania With Mixed Features
- Interventions
- Other: Placebo
- First Posted Date
- 2025-04-30
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 274
- Registration Number
- NCT06951698
- Locations
- 🇺🇸
Local Institution - 0058, Bentonville, Arkansas, United States
🇺🇸Local Institution - 0011, Little Rock, Arkansas, United States
🇺🇸Local Institution - 0005, Anaheim, California, United States
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
- Conditions
- Bipolar Disorder Type I With Mania or Mania With Mixed Features
- Interventions
- Other: Placebo
- First Posted Date
- 2025-04-30
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 274
- Registration Number
- NCT06951711
- Locations
- 🇺🇸
Local Institution - 0014, Little Rock, Arkansas, United States
🇺🇸Local Institution - 0025, Rogers, Arkansas, United States
🇺🇸Local Institution - 0021, Culver City, California, United States
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
- Conditions
- Alzheimer DiseasePsychosis
- Interventions
- First Posted Date
- 2025-04-27
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1046
- Registration Number
- NCT06947941
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-04-27
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 76
- Registration Number
- NCT06946797
- Locations
- 🇺🇸
Alaska Oncology and Hematology, Anchorage, Alaska, United States
🇺🇸Local Institution - 0062, Los Angeles, California, United States
🇺🇸Local Institution - 0063, Boise, Idaho, United States
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 600
- Registration Number
- NCT06937229
- Locations
- 🇺🇸
Local Institution - 2609, Chandler, Arizona, United States
🇺🇸Local Institution - 1619, Scottsdale, Arizona, United States
🇺🇸Local Institution - 2620, Canoga Park, California, United States
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
- Conditions
- MesotheliomaNon Small Cell Lung CancerMalignant Peripheral Nerve Sheath TumorsSolid TumorPancreatic AdenocarcinomaAdvanced Solid Tumor
- Interventions
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 320
- Registration Number
- NCT06937970
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Sarah Cannon Research Institute (SCRI) - HealthONE Location, Denver, Colorado, United States
🇺🇸Rocky Mountain Cancer Centers, LLP - Oncology, Lone Tree, Colorado, United States